Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
Pharma Two B and Hepion Pharmaceuticals (Nasdaq: HEPA) have filed a registration statement on Form F-4 with the SEC for their proposed merger. The filing contains a proxy statement/prospectus detailing the transaction announced on July 22, 2024. Pharma Two B, developing P2B001 for Parkinson's Disease, aims to go public on Nasdaq through this merger with Hepion, which has been developing treatments for liver diseases including NASH and HCC.
The merger, approved by both companies' boards, is expected to close in Q4 2024, subject to stockholder and regulatory approvals. Post-merger, the combined entity will operate as Pharma Two B and trade under the ticker symbol "PHTB". The transaction is supported by financial advisors A.G.P./Alliance Global Partners for Hepion and Laidlaw & Company (UK) for Pharma Two B, along with respective legal advisors.
Pharma Two B e Hepion Pharmaceuticals (Nasdaq: HEPA) hanno presentato una dichiarazione di registrazione sul modulo F-4 alla SEC per la loro proposta di fusione. Il deposito contiene una dichiarazione di delega/prospetto che dettaglia la transazione annunciata il 22 luglio 2024. Pharma Two B, che sta sviluppando P2B001 per il morbo di Parkinson, mira a diventare pubblica su Nasdaq tramite questa fusione con Hepion, che ha sviluppato trattamenti per malattie del fegato, tra cui NASH e HCC.
La fusione, approvata dai consigli di amministrazione di entrambe le aziende, dovrebbe concludersi nel quarto trimestre del 2024, soggetta all'approvazione degli azionisti e delle autorità di regolamentazione. Dopo la fusione, l'entità combinata opererà come Pharma Two B e scambierà con il simbolo borsa 'PHTB'. La transazione è supportata dai consulenti finanziari A.G.P./Alliance Global Partners per Hepion e Laidlaw & Company (UK) per Pharma Two B, insieme ai rispettivi consulenti legali.
Pharma Two B y Hepion Pharmaceuticals (Nasdaq: HEPA) han presentado una declaración de registro en el Formulario F-4 ante la SEC para su propuesta de fusión. La presentación contiene una declaración de poder/prospecto que detalla la transacción anunciada el 22 de julio de 2024. Pharma Two B, que está desarrollando P2B001 para la enfermedad de Parkinson, tiene como objetivo salir a bolsa en Nasdaq a través de esta fusión con Hepion, que ha estado desarrollando tratamientos para enfermedades del hígado, incluyendo NASH y HCC.
La fusión, aprobada por las juntas de ambas empresas, se espera que se cierre en el cuarto trimestre de 2024, sujeta a las aprobaciones de los accionistas y regulatorias. Después de la fusión, la entidad combinada operará como Pharma Two B y se comercializará bajo el símbolo 'PHTB'. La transacción cuenta con el apoyo de los asesores financieros A.G.P./Alliance Global Partners para Hepion y Laidlaw & Company (Reino Unido) para Pharma Two B, junto con los respectivos asesores legales.
Pharma Two B와 Hepion Pharmaceuticals (Nasdaq: HEPA)는 그들의 제안된 합병을 위해 SEC에 F-4 양식으로 등록 신청서를 제출했습니다. 이 제출물에는 2024년 7월 22일 발표된 거래에 대한 위임장/투자 설명서가 포함되어 있습니다. Pharma Two B는 파킨슨병을 위한 P2B001을 개발하고 있으며, Hepion과의 이 합병을 통해 Nasdaq에 상장할 계획입니다. Hepion은 NASH 및 HCC를 포함한 간 질환 치료제를 개발해왔습니다.
두 회사의 이사회에서 승인된 이 합병은 2024년 4분기에 주주 및 규제 기관의 승인을 조건으로 마감될 것으로 예상됩니다. 합병 후, 결합된 기업은 Pharma Two B로 운영되며, 거래 기호 'PHTB'로 거래됩니다. 이 거래는 Hepion을 위한 A.G.P./Alliance Global Partners와 Pharma Two B를 위한 Laidlaw & Company (UK)의 재정 고문, 그리고 각각의 법률 고문에 의해 지원받고 있습니다.
Pharma Two B et Hepion Pharmaceuticals (Nasdaq: HEPA) ont déposé une déclaration d'enregistrement au formulaire F-4 auprès de la SEC pour leur fusion proposée. Le dépôt contient une déclaration de procuration/prospectus détaillant la transaction annoncée le 22 juillet 2024. Pharma Two B, développant P2B001 pour la maladie de Parkinson, vise à devenir public sur le Nasdaq grâce à cette fusion avec Hepion, qui développe des traitements pour des maladies du foie, y compris NASH et HCC.
La fusion, approuvée par les conseils d'administration des deux entreprises, devrait se conclure au quatrième trimestre 2024, sous réserve de l'approbation des actionnaires et des régulations. Après la fusion, l'entité combinée opérera sous le nom de Pharma Two B et se négociera sous le symbole boursier 'PHTB'. La transaction est soutenue par les conseillers financiers A.G.P./Alliance Global Partners pour Hepion et Laidlaw & Company (Royaume-Uni) pour Pharma Two B, ainsi que par les conseillers juridiques respectifs.
Pharma Two B und Hepion Pharmaceuticals (Nasdaq: HEPA) haben bei der SEC eine Registrierungsanmeldung nach Formular F-4 für ihre vorgeschlagene Fusion eingereicht. Die Anmeldung enthält eine Stimmrechtsvollmacht/-prospekt, die die am 22. Juli 2024 angekündigte Transaktion detailliert. Pharma Two B, das P2B001 für die Parkinson-Krankheit entwickelt, strebt an, durch diese Fusion mit Hepion, das Behandlungen für Lebererkrankungen wie NASH und HCC entwickelt, an die Nasdaq zu gehen.
Die Fusion, die von den Vorständen beider Unternehmen genehmigt wurde, wird voraussichtlich im 4. Quartal 2024 abgeschlossen, vorbehaltlich der Zustimmung der Aktionäre und der Aufsichtsbehörden. Nach der Fusion wird das kombinierte Unternehmen als Pharma Two B agieren und unter dem Börsensymbol 'PHTB' handeln. Die Transaktion wird von den Finanzberatern A.G.P./Alliance Global Partners für Hepion und Laidlaw & Company (UK) für Pharma Two B sowie von den jeweiligen Rechtsberatern unterstützt.
- Potential for increased market presence and funding through Nasdaq listing
- Merger combines Pharma Two B's late-stage Parkinson's treatment with Hepion's liver disease portfolio
- Transaction expected to close in Q4 2024, indicating swift progress
- Merger subject to stockholder and regulatory approvals, which could delay or prevent completion
- Potential integration challenges and costs associated with the merger
- Uncertainty regarding market reception of the combined company and its diverse drug pipeline
Insights
The filing of the F-4 registration statement marks a important step towards the merger between Pharma Two B and Hepion Pharmaceuticals. This strategic move could potentially create a stronger entity with a diversified pipeline, combining Pharma Two B's Parkinson's Disease candidate and Hepion's liver disease treatments. For investors, this merger represents a significant transformation in both companies' market positions and future prospects.
The planned Nasdaq listing under the ticker 'PHTB' could enhance visibility and liquidity for the combined entity. However, investors should note that the deal is still subject to shareholder and regulatory approvals, introducing some uncertainty. The Q4 2024 expected closing provides a timeline for potential market reactions. Investors should closely monitor the progress of this merger, as it could impact the valuation and growth potential of both companies in the competitive biotech landscape.
The F-4 filing is a critical legal step in the merger process, signaling that the deal is progressing as planned. This document will provide essential information for shareholders and regulators to evaluate the proposed transaction. Key aspects to watch include:
- Disclosure of merger terms and potential risks
- Financial projections for the combined entity
- Governance structure post-merger
The involvement of multiple legal advisors (Sheppard Mullin, Lipa Meir, Meitar and Goodwin Procter) suggests a complex transaction with potential cross-border considerations. Investors should pay attention to any regulatory hurdles, particularly regarding Nasdaq listing requirements and potential antitrust reviews. The successful completion of this merger will depend on navigating these legal complexities effectively.
This merger could create a more robust biopharmaceutical company with a diverse late-stage pipeline. Pharma Two B's P2B001 for Parkinson's Disease and Hepion's treatments for NASH and HCC address significant unmet medical needs in neurology and hepatology, respectively. The combination might lead to:
- Enhanced R&D capabilities
- Potential synergies in clinical development
- Improved access to capital for advancing clinical programs
However, investors should consider the challenges of integrating two different therapeutic areas and the risks associated with late-stage clinical trials. The success of this merger will largely depend on the clinical progress of key pipeline assets and the combined company's ability to navigate the complex regulatory landscape in both neurological and liver diseases.
KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson’s Disease (“PD”) and Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (“Hepion”), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today jointly announced the filing of a registration statement of Pharma Two B on Form F-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the “SEC”).
The Registration Statement contains a proxy statement/prospectus in connection with the proposed merger transaction pursuant to the definitive agreement entered into between Pharma Two B and Hepion (the "Merger Agreement", and the proposed transactions contemplated thereby, the “Proposed Transaction”). While the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides important information about Pharma Two B and Hepion and the Proposed Transaction.
As announced on July 22, 2024, Pharma Two B intends to become a publicly traded company on Nasdaq through a merger transaction with Hepion.
The Proposed Transaction, which has been approved by the respective boards of directors of Pharma Two B and Hepion, is expected to close in the fourth quarter of 2024 and remains subject to approval by both Pharma Two B and Hepion’s respective stockholders, regulatory approval, listing of Pharma Two B's ordinary shares on Nasdaq under the ticker symbol “PHTB” and other customary closing conditions. Upon the anticipated closing of the Proposed Transaction, the combined company will operate under the “Pharma Two B” name.
A.G.P./Alliance Global Partners is serving as financial advisor to Hepion and Sheppard, Mullin, Richter & Hampton LLP is acting as U.S. legal advisor to Hepion and Lipa Meir & Co.is acting as Israeli legal advisor to Hepion. Sullivan & Worcester LLP is serving as legal advisor to A.G.P.
Laidlaw & Company (UK) Ltd. is acting as financial advisor to Pharma Two B. and Meitar Law Offices and Goodwin Procter LLP are acting as legal advisors to Pharma Two B.
About Pharma Two B
Pharma Two B is a private, late-stage pharmaceutical company. Pharma Two B’s mission is to improve patients’ quality of life by developing innovative, value-added combination drugs for neurological disorders, with a clear unmet need, that are based on previously approved oral drugs and that may offer meaningful clinical benefits, as well as improved safety and enhanced convenience. Pharma Two B’s lead product candidate is P2B001. For more information, please visit: www.pharma2b.com.
About P2B001
P2B001 is an investigational, novel, fixed-dose, extended-release combination of pramipexole and rasagiline (0.6 mg/0.75 mg), both at low doses that are not commercially available. Marketed pramipexole and rasagiline are currently indicated for the treatment of PD (as monotherapy and adjunct therapy for early and more advanced patients). P2B001 is being developed for potential use as a first-line therapy for people with PD. Extended release rasagiline is a new and proprietary formulation of rasagiline developed by Pharma Two B.
In a Phase 3 clinical trial, P2B001 demonstrated that it provides benefits comparable with commercially used doses of marketed pramipexole-ER (PramiER) while minimizing associated daytime sleep-related and dopaminergic side effects.
Pharma Two B owns worldwide-granted patents for both pharmaceutical composition and method of treatment with P2B001.
About Hepion Pharmaceuticals
Hepion is a biopharmaceutical company headquartered in Edison, New Jersey, previously focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and shows potential for the treatment of hepatocellular carcinoma (“HCC”) associated with non-alcoholic steatohepatitis (“NASH”), viral hepatitis, and other liver diseases. Hepion’s cyclophilin inhibitor, rencofilstat, was being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease. In December 2023, Hepion’s board of directors approved a strategic restructuring plan to preserve capital by reducing operating costs. Additionally, Hepion initiated a process to explore a range of strategic and financing alternatives focused on maximizing stockholder value within the current financial environment and NASH drug development landscape. On April 19, 2024, Hepion announced that it has begun wind-down activities in its ASCEND- NASH clinical trial. Hepion is continuing efforts, to the extent that cash is available, to provide any value derived from rencofilstat to its shareholders.
Forward-Looking Statements
Certain statements in this press release may be considered “forward-looking statements”. Forward-looking statements generally relate to future events or Hepion’s or Pharma Two B’s future financial or operating performance. For example, express or implied statements regarding Hepion and Pharma Two B's expectations with respect to the Proposed Transaction, including the timing of closing thereof and pro forma ownership of the combined company, the concurrent financing, the cash runway of the combined company; planned timing of New Drug Application (“NDA”) submission, P2B001 potential as a treatment for PD and label expansion, projected net revenues, and related matters, as well as all other statements other than statements of historical fact included in this press release, are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to Hepion or Pharma Two B, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, Hepion’s and Pharma Two B's management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in Hepion’s filings with the SEC. Most of these factors are outside the control of Hepion and/or Pharma Two B and are difficult to predict. In addition to factors disclosed in Hepion’s filings with the SEC, the following factors, among others, could cause actual results and the timing of events to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: the risk that the Proposed Transaction may not be completed in a timely manner or at all, which may adversely affect the price of the securities of Hepion; the inability to meet the closing conditions to the Proposed Transaction, including the failure of Pharma Two B to meet Nasdaq initial listing standards in connection with the consummation of the Proposed Transaction; costs related to the Proposed Transaction and the failure to realize anticipated benefits of the Proposed Transaction or to realize estimated pro forma results with respect thereto as well as other risks associated with biopharmaceutical companies generally, including the risks of filing an NDA, obtaining regulatory approval for any product candidates, commercialization of any approved product, including P2B001 for PD, as well as the total addressable market and potential for success of P2B001, the presentation of financial information in U.S. GAAP, completion of a PCAOB audit of U.S. GAAP financials, as well as other risks set forth in more detail in the Registration Statement. The forward-looking statements are based upon management’s beliefs and assumptions; and other risks and uncertainties identified in the Registration Statement, including those under “Risk Factors” therein, and in other filings with the SEC made by Hepion. Each of Hepion and Pharma Two B undertake no obligation to update these statements for revisions or changes after the date of press release, except as required by law.
No Offer or Solicitation
This press release does not constitute an offer to sell or a solicitation of an offer to buy, or the solicitation of any vote or approval in any jurisdiction in connection with the Proposed Transaction or any related transactions, nor shall there be any sale, issuance or transfer of securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale may be unlawful. Any offering of securities or solicitation of votes regarding the proposed transaction will be made only by means of a proxy statement/prospectus that complies with applicable rules and regulations promulgated under the Securities Act, and the Securities Exchange Act of 1934, as amended, or pursuant to an exemption from the Securities Act or in a transaction not subject to the registration requirements of the Securities Act.
Additional Information and Where to Find It
In connection with the Proposed Transaction, Pharma Two B filed the Registration Statement with the SEC, which includes a preliminary prospectus with respect to its securities to be issued in connection with the Proposed Transaction, and a preliminary proxy statement with respect to Hepion’s stockholder meeting at which Hepion’s stockholders will be asked to vote on the proposed Proposed Transaction and related matters. Each of Hepion and Pharma Two B urge investors, stockholders, and other interested persons to read, when available, the Registration Statement including the proxy statement/prospectus, any amendments thereto, and any other documents filed with the SEC, before making any voting or investment decision because these documents will contain important information about the Proposed Transaction. After the Registration Statement has been declared effective, Pharma Two B and Hepion will mail the definitive proxy statement/prospectus to stockholders of Hepion as of a record date to be established for voting on the Proposed Transaction. Hepion’s stockholders will also be able to obtain a copy of such documents, without charge, by directing a request to: Executive Chairman at info@hepionpharma.com.
Participants in the Solicitation
Pharma Two B and Hepion and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Hepion’s stockholders in connection with the Proposed Transaction. Information about Hepion’s directors and executive officers and their ownership of Hepion’s securities is set forth in Hepion’s filings with the SEC. To the extent that holdings of Hepion’s securities have changed since the amounts printed in Hepion’s Annual Report on Form 10-K/A, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. A list of the names of such directors and executive officers and information regarding their interests in the Proposed Transaction is contained in the proxy statement/prospectus in the Registration Statement. You may obtain free copies of these documents as described in the preceding paragraph.
Contact Information
Hepion Pharmaceuticals
732-902-4000
info@hepionpharma.com
Pharma Two B Ltd.
Dan Teleman, CEO
Email: dan@pharma2b.com
www.pharma2b.com
FAQ
What is the purpose of the merger between Pharma Two B and Hepion Pharmaceuticals (HEPA)?
When is the merger between Pharma Two B and Hepion Pharmaceuticals (HEPA) expected to close?
What will be the ticker symbol for the combined company after the Pharma Two B and Hepion (HEPA) merger?
What key approvals are needed for the Pharma Two B and Hepion Pharmaceuticals (HEPA) merger to proceed?
